Drugs / ASTX727 Dose Escalation
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02103478 | Oct 2014 → Jun 2018 | myelodysplastic syndrome | Astex Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASTX727 Dose Escalation | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02103478 ↗ |
| Action | Inhibit | “Decitabine, a DNA methyltransferase 1 inhibitor or DNA hypomethylating compound” PMID 30926081 ↗ Apr 2019 |
| Modality | Small molecule | “Decitabine, a DNA methyltransferase 1 inhibitor or DNA hypomethylating compound, is not readily orally bioavailable” PMID 30926081 ↗ Apr 2019 |
| Route | Oral | “oral decitabine and cedazuridine were given on days 1-5” PMID 30926081 ↗ Apr 2019 |
| Target | DNMT1 | “Decitabine, a DNA methyltransferase 1 inhibitor or DNA hypomethylating compound” PMID 30926081 ↗ Apr 2019 |